These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35112229)

  • 1. Free Drug Theory - No Longer Just a Hypothesis?
    Summerfield SG; Yates JWT; Fairman DA
    Pharm Res; 2022 Feb; 39(2):213-222. PubMed ID: 35112229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.
    Riede J; Poller B; Huwyler J; Camenisch G
    Drug Metab Dispos; 2017 May; 45(5):523-531. PubMed ID: 28254950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current In Vitro Methods to Determine Hepatic Kp
    Riede J; Camenisch G; Huwyler J; Poller B
    J Pharm Sci; 2017 Sep; 106(9):2805-2814. PubMed ID: 28385545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving approaches on measurements and applications of intracellular free drug concentration and Kp
    Di L; Riccardi K; Tess D
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):733-746. PubMed ID: 34058926
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel Method to Predict In Vivo Liver-to-Plasma K
    Riccardi K; Lin J; Li Z; Niosi M; Ryu S; Hua W; Atkinson K; Kosa RE; Litchfield J; Di L
    Drug Metab Dispos; 2017 May; 45(5):576-580. PubMed ID: 28258068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on binding of drug to serum protein].
    Otagiri M
    Yakugaku Zasshi; 2009 Apr; 129(4):413-25. PubMed ID: 19336995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma protein binding: from discovery to development.
    Bohnert T; Gan LS
    J Pharm Sci; 2013 Sep; 102(9):2953-94. PubMed ID: 23798314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration Dependence of the Unbound Partition Coefficient Kp
    Trünkle C; Lechner C; Korr D; Bouché L; Barak N; Fernández-Montalván A; Süssmuth RD; Reichel A
    Drug Metab Dispos; 2020 Jul; 48(7):553-562. PubMed ID: 32357973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
    Li R; Barton HA; Varma MV
    Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of recovery on fraction unbound using equilibrium dialysis.
    Di L; Umland JP; Trapa PE; Maurer TS
    J Pharm Sci; 2012 Mar; 101(3):1327-35. PubMed ID: 22161810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels.
    Yin N; Pei J; Lai L
    Mol Biosyst; 2013 Jun; 9(6):1381-9. PubMed ID: 23478789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and the drug-target residence time concept.
    Dahl G; Akerud T
    Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
    Jones RD; Jones HM; Rowland M; Gibson CR; Yates JW; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4074-89. PubMed ID: 21452299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transporters in absorption, distribution, and elimination.
    Scherrmann JM
    Chem Biodivers; 2009 Nov; 6(11):1933-42. PubMed ID: 19937831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.